GlassScriptPhysician profile
Thomas W Mccormack
NPI 1740298728
$161,790.82
in general payments reported to CMS, 2019-2025
36 companies · $21K in 2025
The $21K reported for 2025 was more than what 97% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $47K · 2020: $4,409 · 2021: $10K · 2022: $18K · 2023: $27K · 2024: $33K · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $35K · Honoraria: $17K · Travel and Lodging: $14K · Food and Beverage: $9,696 · Consulting Fee: $4,500 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $1,500 · Education: $213.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $34,550.00 |
| Honoraria | $17,350.00 |
| Travel and Lodging | $14,036.26 |
| Food and Beverage | $9,695.59 |
| Consulting Fee | $4,500.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $1,500.00 |
| Education | $212.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $41,153.68 | 2021-2025 | Qelbree, Qelbree |
| Abbvie INC. | $36,354.92 | 2021-2025 | |
| Allergan, INC. | $34,215.14 | 2019-2021 | |
| Axsome Therapeutics, INC. | $19,912.66 | 2022-2025 | Auvelity |
| Ironshore Pharmaceuticals INC. | $13,540.11 | 2019-2024 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $6,167.43 | 2019-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,245.68 | 2021-2025 | Caplyta |
| Alkermes, INC. | $1,096.69 | 2021-2025 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $1,003.43 | 2019-2025 | Invega Sustenna, Spravato |
| Vanda Pharmaceuticals INC. | $891.24 | 2019-2025 | Fanapt, Hetlioz |
| Neurocrine Biosciences, INC. | $881.02 | 2019-2025 | Ingrezza |
| Lundbeck LLC | $804.76 | 2019-2025 | Rexulti, Abilify Maintena, Brintellix |
| Teva Pharmaceuticals USA, INC. | $633.75 | 2022-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $624.41 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Tris Pharma INC | $622.71 | 2019-2025 | Dyanavel Xr |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $473.71 | 2019-2022 | |
| Noven Therapeutics, LLC | $261.39 | 2020-2025 | Xelstrym, Secuado |
| Corium, LLC | $244.12 | 2022-2025 | Azstarys |
| Bausch Health US, LLC | $243.28 | 2019-2025 | Wellbutrin, Aplenzin |
| Harmony Biosciences LLC | $234.49 | 2023-2025 | Wakix |
| Indivior INC. | $172.46 | 2023-2025 | Sublocade, Perseris |
| Jazz Pharmaceuticals INC. | $167.39 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $144.93 | 2022-2024 | Quviviq |
| Eisai INC. | $115.48 | 2020-2021 | |
| Arbor Pharmaceuticals, INC. | $97.45 | 2019-2020 | |
| Adlon Therapeutics L.P. | $78.56 | 2019-2021 | |
| Collegium Pharmaceutical, INC. | $77.41 | 2025 | Jornay Pm |
| Stryker Corporation | $73.06 | 2023-2024 | Variax, T2 Alpha |
| E.R. Squibb & Sons, L.L.C. | $65.12 | 2024-2025 | Cobenfy |
| Owp Pharmaceuticals, INC. | $54.57 | 2019-2021 | |
| Tempus Ai, INC | $38.71 | 2024 | |
| Brainsway USA INC | $24.51 | 2024 | Brainsway Deep Tms System |
| Noven Pharmaceuticals, INC. | $22.33 | 2023 | Xelstrym |
| Livanova USA, INC. | $20.73 | 2023 | Vns Therapy Symmetry Model 8103 Generator |
| Neuronetics, INC. | $18.59 | 2023 | Neurostar Tms Therapy System |
| Shire North American Group INC | $14.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Mccormack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.